Tyler Olson is a Overland Park, Kansas based male Ophthalmologist who is specialized in Ophthalmology. Active license number of Tyler Olson is 04-51014 for Ophthalmology in Kansas. Tyler Olson is medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, patients can be prescribed vision services, including glasses and contact lenses.
Complete Profile:
Tyler Olson speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Ophthalmology
Credentials:
MD
Gender:
Male
Practice Address:
5520 College Blvd Ste 201, Overland Park, Kansas, 66211-1658
Phone:
913-491-3737
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1285253823
NPI Enumeration Date:
14 Apr, 2020
NPI Last Update On:
02 Sep, 2025
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Tyler Olson are as mentioned below.
License Number
Specialization
State
Status
04-51014
Ophthalmology
Kansas
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
5520 College Blvd Ste 201, Overland Park, Kansas
Zip:
66211-1658
Phone Number:
913-491-3737
Fax Number:
--
Patients can reach Tyler Olson at 5520 College Blvd Ste 201, Overland Park, Kansas or can call to book an appointment on 913-491-3737. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 October, 2025.